Half Year 2025 Almirall SA Earnings Call Transcript
Key Points
- Almirall SA (LBTSF) reaffirmed its full-year 2025 guidance and mid-term outlook, indicating confidence in its growth strategy.
- The company's medical dermatology portfolio, particularly Ebglyss and Ilumetri, continues to show strong sales growth, with Ebglyss achieving significant market uptake in Germany and other European countries.
- Almirall SA (LBTSF) has expanded its collaboration with Simcere to include new bispecific antibodies for immunodermatology diseases, enhancing its R&D pipeline.
- The company reported a 13% year-on-year increase in net sales for the first half of 2025, driven by its European dermatology portfolio.
- Almirall SA (LBTSF) maintains a low net debt-to-EBITDA ratio of 0.4 times, providing financial flexibility for potential acquisitions and investments.
- The US business recorded a year-on-year decline, with ongoing pressure from generic competition affecting products like Tazorac and Axone.
- Gross margin is expected to face continued pressure due to evolving sales mix and higher royalty levels linked to growth.
- R&D spending increased by 27% year-on-year, which may impact short-term profitability despite being aligned with long-term growth strategies.
- SG&A expenses rose by 8% to EUR251 million, reflecting continued investment in product rollouts, which could strain financial resources.
- The company faces challenges in stabilizing its US operations, with plans to achieve EBITDA neutrality by the end of the year still in progress.
Good day, and thank you for standing by. Welcome to the Almirall H1 2025 financial results and business update conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Pablo Divasson, Head of Investor Relations. Please go ahead.
Thank you very much, Heidi, and good morning, everyone. Thank you for joining us today's quarterly earnings update and review of Almirall's first half-year financial results of 2025. As always, we are sharing the slides we are using today in the investor section of our website at almirall.com.
Please move to slide number 2. Let me remind you that the information presented in this call contains forward-looking statements which involve known and unknown risk, uncertainties, and other factors that may cause actual results to materially differ from what we are sharing today.
Please move to slide number 3. Presented today are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
